E
Edgar T. Overton
Researcher at University of Alabama at Birmingham
Publications - 162
Citations - 5484
Edgar T. Overton is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 37, co-authored 138 publications receiving 4162 citations. Previous affiliations of Edgar T. Overton include Washington University in St. Louis & University of Alabama.
Papers
More filters
Journal ArticleDOI
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
David L. Wyles,Peter Ruane,Mark S. Sulkowski,Douglas T. Dieterich,Anne F Luetkemeyer,Timothy R. Morgan,Kenneth E. Sherman,Robin Dretler,Dawn Fishbein,Joseph Gathe,Sarah Henn,Federico Hinestrosa,Charles Huynh,Cheryl McDonald,Anthony Mills,Edgar T. Overton,Moti Ramgopal,Bruce Rashbaum,Graham Ray,Anthony Scarsella,Joseph Yozviak,Fiona McPhee,Zhaohui Liu,Eric Hughes,Philip D. Yin,Stephanie Noviello,Peter Ackerman +26 more
TL;DR: Among previously untreated HIV-HCV coinfected patients receiving daclatasvir plus sofosbuvir for HCV infection, the rate of sustained virologic response across all genotypes was 97.3% after 12 weeks of treatment and 76.0% after 8 weeks, respectively.
Journal ArticleDOI
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Katharine J. Bar,Michael C. Sneller,Linda Harrison,J. Shawn Justement,Edgar T. Overton,Mary E. Petrone,D. Brenda Salantes,Catherine Seamon,Benjamin Scheinfeld,Richard Kwan,Gerald H. Learn,Michael A. Proschan,Edward F. Kreider,Jana Blazkova,Mark Bardsley,Eric W. Refsland,Michael Messer,Katherine E Clarridge,Nancy B Tustin,Patrick J Madden,KaSaundra Oden,Sijy O'Dell,Bernadette Jarocki,Andrea Shiakolas,Randall Tressler,Nicole A. Doria-Rose,Robert T. Bailer,Julie E. Ledgerwood,Edmund V. Capparelli,Rebecca M. Lynch,Barney S. Graham,Susan Moir,Richard A. Koup,John R. Mascola,James A. Hoxie,Anthony S. Fauci,Pablo Tebas,Tae-Wook Chun +37 more
TL;DR: Analyses of virus populations before ART as well as before and after ART interruption showed that VRC01 exerted pressure on rebounding virus, resulting in restriction of recrudescent viruses and selection for preexisting and emerging antibody neutralization-resistant virus.
Journal ArticleDOI
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Raphael J. Landovitz,Deborah Donnell,Meredith E. Clement,Brett Hanscom,Leslie Cottle,Lara E. Coelho,Robinson Cabello,Suwat Chariyalertsak,Eileen F. Dunne,Ian Frank,Jorge A Gallardo-Cartagena,Aditya H Gaur,Pedro Gonzales,Ha V Tran,Juan C Hinojosa,Esper G Kallas,Colleen F Kelley,Marcelo H. Losso,J Valdez Madruga,Keren Middelkoop,Nittaya Phanuphak,Breno Santos,Omar Sued,Javier Valencia Huamaní,Edgar T. Overton,Shobha Swaminathan,Carlos del Rio,Roy M. Gulick,Paul G. Richardson,Philip Sullivan,Estelle Piwowar-Manning,Mark A. Marzinke,Craig W. Hendrix,Maoji Li,Zhe Wang,Jeanne M. Marrazzo,Eric S. Daar,Aida Asmelash,Todd T. Brown,Peter J. Anderson,Susan H. Eshleman,Marcus Bryan,Cheryl Blanchette,Jonathan Lucas,Christina Psaros,Steven A. Safren,Jeremy Sugarman,Hyman M. Scott,Joseph J. Eron,Sheldon D. Fields,Nirupama Sista,Kailazarid Gomez-Feliciano,Andrea Jennings,Ryan Kofron,Timothy H. Holtz,Katherine Shin,James F. Rooney,Kimberly Y. Smith,William Spreen,David J. Margolis,Alex R. Rinehart,Adeola Adeyeye,Myron S. Cohen,Marybeth McCauley,Beatriz Grinsztejn,Hptn (PopART) Study Team +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI
Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.
Kristin Mondy,Edgar T. Overton,Jessica R. Grubb,Shao Tong,Warren Seyfried,William G. Powderly,Kevin E. Yarasheski +6 more
TL;DR: The prevalence of metabolic syndrome is high among HIV-infected persons, but not higher than the prevalence among HIV -uninfected people, and traditional risk factors play a more significant role in the development of metabolic Syndrome than do HIV treatment-associated factors.
Journal ArticleDOI
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe Orkin,Keikawus Arastéh,Miguel de Górgolas Hernández-Mora,Vadim Pokrovsky,Edgar T. Overton,Pierre-Marie Girard,Shinichi Oka,Sharon Walmsley,Chris Bettacchi,Cynthia Brinson,Patrick Philibert,Johan Lombaard,Marty St. Clair,Herta Crauwels,Susan L. Ford,Parul Patel,Vasiliki Chounta,Ronald D'Amico,Simon Vanveggel,David Dorey,Amy Cutrell,Sandy Griffith,David A. Margolis,Peter Williams,Wim Louis Julien Parys,Kimberly Y. Smith,William Spreen +26 more
TL;DR: Therapy with long-acting cabotegravir plus rilpivirine was noninferior to oral therapy with dolutegravIR-abacavir-lamivudine with regard to maintaining HIV-1 suppression.